A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Trial Profile

A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Insulin glulisine (Primary)
  • Indications Down syndrome
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 10 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 06 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top